Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb23104 in Advanced Sarcoma
NCT05879185Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of izuralimab in sarcoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2023; status: terminated.
02
Drugs
izuralimab
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT05879185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879185.